Eiropas Savienība - latviešu - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Latvija - latviešu - Zāļu valsts aģentūra

astrazeneca ab, sweden - budezonīds - suspensija izsmidzināšanai - 0,5 mg/ml

Latvija - latviešu - Zāļu valsts aģentūra

astrazeneca ab, sweden - budezonīds - suspensija izsmidzināšanai - 0,5 mg/ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple mieloma - antineoplastiski līdzekļi - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Latvija - latviešu - Zāļu valsts aģentūra

amdipharm limited, ireland - lanreotīds - Šķīdums injekcijām pilnšļircē - 60 mg

Latvija - latviešu - Zāļu valsts aģentūra

amdipharm limited, ireland - lanreotīds - Šķīdums injekcijām pilnšļircē - 90 mg

Latvija - latviešu - Zāļu valsts aģentūra

amdipharm limited, ireland - lanreotīds - Šķīdums injekcijām pilnšļircē - 120 mg

Latvija - latviešu - Zāļu valsts aģentūra

astrazeneca a.e., greece - budezonīds - suspensija izsmidzināšanai - 0,5 mg/ml

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Latvija - latviešu - Zāļu valsts aģentūra

medochemie ltd., cyprus - deksametazona fosfāts - Šķīdums injekcijām/infūzijām - 4 mg/ml